Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions

Transfusion

Volumn 59, Issue 12, 2019, Pages 3727-3735

  Arnason, Niels Arni ^a   Johannson, Freyr ^b   Landrö, Ragna ^a   Hardarsson, Björn ^a   Irsch, Johannes ^c   Gudmundsson, Sveinn ^a   Rolfsson, Ottar ^b   Sigurjonsson, Olafur E ^a,d  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c Cerus Europe BV   (Netherlands)

^d REYKJAVIK UNIVERSITY   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; CD40 LIGAND; LIPOCORTIN 5; MICRORNA; MICRORNA 1260B; MICRORNA 146A 5P; MICRORNA 17 3P; MICRORNA 20A 5P; MICRORNA 326; MICRORNA 96 5P; PADGEM PROTEIN; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; FUROCOUMARIN DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; HUMAN; HUMAN CELL; ILLUMINATION; LEUKOCYTE COUNT; MRNA EXPRESSION LEVEL; PATHOGEN CLEARANCE; PLATELET COUNT; PROTEIN BINDING; PROTEIN EXPRESSION; QUALITY CONTROL; THROMBOCYTE ACTIVATION; THROMBOCYTE METABOLISM; THROMBOCYTE PRESERVATION; ULTRAVIOLET A RADIATION; UPREGULATION; BLOOD BANK; BLOOD STORAGE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; METABOLISM; POLYMERASE CHAIN REACTION; PROCEDURES; RADIATION RESPONSE; THROMBOCYTE; ULTRAVIOLET RADIATION;

BLOOD BANKS; BLOOD PLATELETS; BLOOD PRESERVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FUROCOUMARINS; HUMANS; MICRORNAS; POLYMERASE CHAIN REACTION; ULTRAVIOLET RAYS;

EID: 85074580314     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.15575     Document Type: Article

References (72)

1. Hogman CF. Storage of blood components. Curr Opin Hematol 1999;6:427-31.
2. Vasconcelos E, Figueiredo AC, Seghatchian J. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis. Transfus Apher Sci 2003;29:13-6.
3. Schrezenmeier H et al. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007;47:644-52.
4. Pietersz RN et al. Bacterial contamination in platelet concentrates. Vox Sang 2014;106:256-83.
5. Kleinman S, Reed W, Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 2013;53:1603-18.
6. Spindler-Raffel E et al. Enlargement of the WHO international repository for platelet transfusion-relevant bacteria reference strains. Vox Sang 2017;112:713-22.
7. Hong H et al. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood 2016;127:496-502.
8. Kocazeybek B et al. Prospective evaluation of platelets prepared by single and random methods during 5 days of storage: aspects related to quality and quantity. Transfus Apher Sci 2002;26:29-34.
9. Akay OM et al. Platelet function testing during 5-day storage of single and random donor plateletpheresis. Transfus Apher Sci 2007;36:285-9.
10. Murphy S, Sayar SN, Gardner FH. Storage of platelet concentrates at 22 degrees C. Blood 1970;35(4):549-557. Blood 2016;128:1155.
11. Chernoff A, Snyder EL. The cellular and molecular basis of the platelet storage lesion: a symposium summary. Transfusion 1992;32:386-90.
12. Devine DV, Serrano K. The platelet storage lesion. Clin Lab Med 2010;30:475-87.
13. Shrivastava M. The platelet storage lesion. Transfus Apher Sci 2009;41:105-13.
14. Singh S et al. Platelet storage lesion in interim platelet unit concentrates: a comparison with buffy-coat and apheresis concentrates. Transfus Apher Sci 2017;56:870-4.
15. Shams Hakimi C et al. In vitro assessment of platelet concentrates with multiple electrode aggregometry. Platelets 2015;26:132-7.
16. Waters L et al. Refrigeration, cryopreservation and pathogen inactivation: an updated perspective on platelet storage conditions. Vox Sang 2018;113:317-28.
17. Rijkers M et al. Evaluation of the role of the GPIb-IX-V receptor complex in development of the platelet storage lesion. Vox Sang 2016;111:247-56.
18. Charlton A et al. Where did platelets go in 2012? A survey of platelet transfusion practice in the North of England. Transfus Med 2014;24:213-8.
19. Shah A, Stanworth SJ, McKechnie S. Evidence and triggers for the transfusion of blood and blood products. Anaesthesia 2015;70(Suppl 1):10-9, e3-5.
20. Mohr H et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009;49:2612-24.
21. Pelletier JP, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006;19:205-42.
22. Lin L et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
23. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001;38(4 Suppl 11):4-11.
24. Johnson L et al. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system. Transfus Med 2013;23:121-9.
25. Apelseth TO et al. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007;47:653-65.
26. Kaiser-Guignard J et al. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014;28:235-41.
27. Sandgren P, Diedrich B. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function. Vox Sang 2015;108:340-9.
28. Hechler B et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013;53:1187-200.
29. Abonnenc M et al. In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step. Blood Transfus 2015;13:255-64.
30. van Rhenen D et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
31. McCullough J et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534-41.
32. Nussbaumer W et al. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients. Vox Sang 2017;112:249-56.
33. Estcourt LJ et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2017;7:Cd009072.
34. Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012;103:322-30.
35. Slichter SJ et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006;46:731-40.
36. Lozano M et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011;153:393-401.
37. Garban F et al. Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial. JAMA Oncol 2018;4:468-75.
38. Garraud O, Lozano M. Pathogen inactivation/reduction technologies for platelet transfusion: where do we stand? Transfus Clin Biol 2018;25:165-71.
39. Garraud O. Pathogen reduction or inactivation technologies for platelet components: does decision making have to await further clinical trials? Transfus Apher Sci 2018;57:797-8.
40. Amato M et al. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre. Vox Sang 2017;112:47-55.
41. Knutson F et al. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015;109:343-52.
42. Kondkar AA et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010;8:369-78.
43. Nagalla S et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011;117:5189-97.
44. Edelstein LC, Bray PF. MicroRNAs in platelet production and activation. Blood 2011;117:5289-96.
45. Edelstein LC et al. MicroRNAs in platelet production and activation. J Thromb Haemost 2013;11(Suppl 1)):340-50.
46. Edelstein LC et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med 2013;19:1609-16.
47. Basak I et al. miR-15a-5p regulates expression of multiple proteins in the megakaryocyte GPVI signaling pathway. J Thromb Haemost 2019;17:511-24.
48. Provost P. Platelet microRNAs. In: Michelson AD, editors. Platelets. London: Academic; 2013. p. 91-101.
49. Guo H et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466:835-40.
50. Friedman RC et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
51. Miranda KC et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006;126:1203-17.
52. Gnatenko DV et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003;101:2285-93.
53. Bugert P et al. Messenger RNA profiling of human platelets by microarray hybridization. Thromb Haemost 2003;90:738-48.
54. Rowley JW et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011;118:e101-11.
55. Ple H et al. The repertoire and features of human platelet microRNAs. PLoS One 2012;7:e50746.
56. Landry P et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009;16:961-6.
57. Kannan M et al. Membrane array-based differential profiling of platelets during storage for 52 miRNAs associated with apoptosis. Transfusion 2009;49:1443-50.
58. Osman A et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets 2015;26:154-63.
59. Yu S et al. Detection of apoptosis-associated microRNA in human apheresis platelets during storage by quantitative real-time polymerase chain reaction analysis. Blood Transfus 2014;12:541-7.
60. Osman A et al. Differential Expression Analysis by RNA-Seq reveals perturbations in the platelet mRNA transcriptome triggered by pathogen reduction systems. PLoS One 2015;10:e0133070.
61. Edelstein LC, Bray PF. Small RNAs as potential platelet therapeutics. Handb Exp Pharmacol 2012;210:435-45.
62. Pontes TB et al. The miRNA profile of platelets stored in a blood bank and its relation to cellular damage from storage. PLoS One 2015;10:e0129399.
63. Dahiya N et al. Platelet MicroRNAs: an overview. Transfus Med Rev 2015;29:215-9.
64. Simon LM et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood 2014;123:e37-45.
65. Prudent M et al. Proteome changes in platelets after pathogen inactivation—an interlaboratory consensus. Transfus Med Rev 2014;28:72-83.
66. Prudent M et al. Proteomic analysis of Intercept-treated platelets. J Proteomics 2012;76:316-28.
67. Sut C et al. The non-hemostatic aspects of transfused platelets. Front Med (Lausanne) 2018;5:42.
68. Ren Q et al. Endobrevin/VAMP-8 is the primary v-SNARE for the platelet release reaction. Mol Biol Cell 2007;18:24-33.
69. Van Aelst B et al. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro. Vox Sang 2015;108:328-39.
70. Van Aelst B et al. Psoralen and ultraviolet A light treatment directly affects phosphatidylinositol 3-kinase signal transduction by altering plasma membrane packing. J Biol Chem 2016;291:24364-76.
71. Feys HB, Van Aelst B, Compernolle V. Biomolecular consequences of platelet pathogen inactivation methods. Transfus Med Rev 2019;33:29-34.
72. Devine DV. Pathogen inactivation strategies to improve blood safety: let's not throw pathogen-reduced platelets out with their bath water. JAMA Oncol 2018;4:458-59.